Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well vismodegib works in treating younger patients with
recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells.